The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
Ideaya eyes neoadjuvant uveal melanoma
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
